Canada

Canada has for over 45 years, had a publicly funded national healthcare system designed to ensure residents receive “reasonable access” to “medically necessary” health-care services, regardless of their financial means. However, unlike many of its European counterparts, Canada has a decentralised system, comprising of 13 separate provincial and territorial health insurance plans. These plans determine how best to organize, manage, and deliver health care within their jurisdictions, guided by common values such as equity and solidarity, and are responsible for meeting basic standards of coverage.


buprenorphine (Sublocade)

Generic Name: buprenorphine Brand Name: Sublocade Manufacturer: Indivior Canada Ltd. Indications: Opioid use disorder, treatment Manufacturer Requested Reimbursement Criteria1: ​For the treatment of moderate-to-severe opioid use disorder in adults. SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support. Submission Type: New Project […]


erenumab (TBC)

Generic Name: erenumab Brand Name: TBC Manufacturer: Novartis Pharmaceuticals Canada Inc. Indications: Migraine Manufacturer Requested Reimbursement Criteria1: For the prevention of migraine in adults with at least 8 migraine days per month who have previously failed at least two migraine preventive therapies due to lack of efficacy, intolerance, or clinical […]


efinaconazole (Jublia)

Generic Name: efinaconazole Brand Name: Jublia Manufacturer: Valeant Canada LP Indications: Onychomycosis Manufacturer Requested Reimbursement Criteria1: ​For the topical treatment of mild to moderate onychomycosis (tinea unguium) of toenails without lunula involvement due to Trichophyton rubrum and Trichophyton mentagrophytes in immunocompetent adult patients. Submission Type: New Project Status: Pending Call […]


Nusinersen (Spinraza)

Generic Name: Nusinersen Brand Name: Spinraza Manufacturer: Biogen Canada Inc. Indications: Spinal Muscular Atrophy Manufacturer Requested Reimbursement Criteria1: ​That nusinersen be reimbursed for the treatment of 5q Spinal Muscular Atrophy (SMA) [including presymptomatic, Types I, II and III patients]. Submission Type: Resubmission Project Status: Pending Call For Patient Input: June […]


tofacitinib (Xeljanz)

Generic Name: tofacitinib Brand Name: Xeljanz Manufacturer: Pfizer Canada Inc. Indications: Arthritis, Psoriatic Manufacturer Requested Reimbursement Criteria1: ​For the treatment of adult patients with active psoriatic arthritis (PsA) when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. Submission Type: New Indication Project Status: Pending Call For […]


cerliponase alfa (Brineura)

Generic Name: cerliponase alfa Brand Name: Brineura Manufacturer: Biomarin Pharmaceutical (Canada) Inc. Indications: Neuronal Ceroid Lipofuscinosis Type 2 Manufacturer Requested Reimbursement Criteria1: ​​Indicated for patients with CLN2 disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency or Neuronal Ceroid Lipofuscinosis type 2. Submission Type: New Project Status: Pending Call For Patient […]


Tiotropium bromide (Spiriva Respimat)

Generic Name: Tiotropium bromide Brand Name: Spiriva Respimat Manufacturer: Boehringer Ingelheim (Canada) Ltd. Indications: Chronic Obstructive Pulmonary Disease (COPD) Submission Type: New Project Status: Complete Date Recommendation Issued: July 16, 2015 Recommendation Type: List with clinical criteria and/or conditions Tags pulmonary disease, chronic obstructive, copd


ledipasvir, sofosbuvir (Harvoni)

Generic Name: ledipasvir, sofosbuvir Brand Name: Harvoni Manufacturer: Gilead Sciences Canada Inc. Indications: Hepatitis C, chronic Submission Type: Request For Advice Project Status: Complete Date Recommendation Issued: May 18, 2016 Recommendation Type: Reimburse with clinical criteria and/or conditions Tags hepatitis c, hepatitis


Empagliflozin (Jardiance)

Generic Name: Empagliflozin Brand Name: Jardiance Manufacturer: Boehringer Ingelheim (Canada) Ltd. Indications: Diabetes mellitus (Type 2) Submission Type: Pre-NOC Project Status: Complete Date Recommendation Issued: October 15, 2015 Recommendation Type: List with clinical criteria and/or conditions Tags diabetes mellitus, type 2, diabetes


tofacitinib (Xeljanz)

Generic Name: tofacitinib Brand Name: Xeljanz Manufacturer: Pfizer Canada Inc. Indications: Ulcerative colitis Manufacturer Requested Reimbursement Criteria1: ​Indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) with an inadequate response, loss of response or intolerance to either conventional UC therapy or a biological agent […]


sucroferric oxyhydroxide (Velphoro )

Generic Name: sucroferric oxyhydroxide Brand Name: Velphoro Manufacturer: Vifor Fresenius Medical Care Renal Pharma Indications: Hyperphosphatemia, end-stage renal disease Manufacturer Requested Reimbursement Criteria1: ​The control of serum phosphorus levels in adult patients with end-stage renal disease (ESRD) on dialysis. Submission Type: New Project Status: Pending Call For Patient Input: May […]


crisaborole (TBC )

Generic Name: crisaborole Brand Name: TBC Manufacturer: Pfizer Canada Inc. Indications: atopic dermatitis Manufacturer Requested Reimbursement Criteria1: ​For treatment of mild to moderate atopic dermatitis in patients 2 years of age and older who have failed or are intolerant to a topical corticosteroid treatment. Submission Type: New Project Status: Pending Call […]


rivaroxaban (Xarelto)

Generic Name: rivaroxaban Brand Name: Xarelto Manufacturer: Bayer Inc. Manufacturer Requested Reimbursement Criteria1: ​For use in combination with low-dose ASA, for the prevention of stroke, myocardial infarction and cardiovascular death in patients with concomitant coronary artery disease (CAD) or peripheral artery disease (PAD). Submission Type: New Indication Project Status: Pending […]


Drugs for the Management of Rheumatoid Arthritis

Key Messages For rheumatoid arthritis patients with moderate to severe disease in whom treatment with methotrexate has failed or who are intolerant to methotrexate, conventional synthetic disease-modifying antirheumatic drugs (alone or in combination), biologics (including biosimilars), and targeted synthetic disease-modifying antirheumatic drugs appear to be effective for different outcomes. It […]


fluticasone furoate/vilanterol (Breo Ellipta )

Generic Name: fluticasone furoate/vilanterol Brand Name: Breo Ellipta Manufacturer: GlaxoSmithKline Inc. Indications: Asthma Manufacturer Requested Reimbursement Criteria1: ​After considering the new data from a pragmatic randomized controlled trial representative of everyday clinical practice, Breo Ellipta is clinically more effective and cost-effective at improving asthma control than usual care, which included […]


bictegravir/emtricitabine/tenofovir alafenamide (TBC)

Generic Name: bictegravir/emtricitabine/tenofovir alafenamide Brand Name: TBC Manufacturer: Gilead Sciences Canada, Inc. Indications: HIV-1 infection Manufacturer Requested Reimbursement Criteria1: ​For the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults. Submission Type: New Combination Project Status: Pending Call For Patient Input: April 2, 2018 Patient Input Closed: May 22, 2018 […]


ertugliflozin and metformin (TBC)

Generic Name: ertugliflozin and metformin Brand Name: TBC Manufacturer: Merck Canada Inc. Indications: Diabetes mellitus, Type 2 Manufacturer Requested Reimbursement Criteria1: Added on to metformin for patients who have inadequate glycemic control on metformin and have a contraindication or intolerance to a sulfonylurea, or To replace the individual components of […]


ertugliflozin (TBC)

Generic Name: ertugliflozin Brand Name: TBC Manufacturer: Merck Canada Inc. Indications: Diabetes mellitus, Type 2 Manufacturer Requested Reimbursement Criteria1: As monotherapy for patients who have inadequate glycemic control and for whom metformin or a sulfonylurea is inappropriate due to contraindications or intolerance. Add-on to metformin for patients who have inadequate […]


lixisenatide + insulin glargine (Soliqua)

Generic Name: lixisenatide + insulin glargine Brand Name: Soliqua Manufacturer: sanofi-aventis Canada Inc. Indications: Diabetes mellitus, Type 2 Manufacturer Requested Reimbursement Criteria1: ​As per indication. Submission Type: New Combination Project Status: Pending Call For Patient Input: March 21, 2018 Patient Input Closed: May 10, 2018 Anticipated Date: April 19, 2018 […]